



US005766873A

United States Patent [19]

Noble et al.

[11] **Patent Number:** **5,766,873**[45] **Date of Patent:** **Jun. 16, 1998**[54] **INTRACELLULAR GLUTATHIONE RAISING
AGENTS FOR THERAPEUTIC
TREATMENTS**[75] **Inventors:** **Mark David Noble; Margot Mayer,**
both of London, England[73] **Assignee:** **Lugwig Institute for Cancer
Research, New York, N.Y.**[21] **Appl. No.:** **189,474**[22] **Filed:** **Jan. 31, 1994**[51] **Int. Cl.⁶** **C12Q 1/26**[52] **U.S. Cl.** **435/25; 424/94.4**[58] **Field of Search** 424/85.1, 94.4;
530/351, 399; 435/25[56] **References Cited****U.S. PATENT DOCUMENTS**

4,985,241 1/1991 Zimmerman et al. 424/85.1

OTHER PUBLICATIONS

Fiers et al., Immunol. Letters, vol. 16, pp. 219-226 1987.

Rothstein et al., Immunology Series, vol. 56, pp. 453-481,
1992.

Bone, Annals of Int. Med., vol. 115, pp. 457-469, 1991.

Primary Examiner—Chhaya D. Sayala*Attorney, Agent, or Firm*—Klauber & Jackson[57] **ABSTRACT**

The invention is directed to therapeutic methods for treating diseases associated with tumour necrosis factor-alpha (TNF- α) induced cell toxicity and/or complement induced cell toxicity, and improved methods for treating diseases whose therapy comprises the administration of n-acetylcysteine.

2 Claims, 8 Drawing Sheets